Fusion Pharmaceuticals Inc. Purchase Agreements
9 Contracts & Agreements
- Securities Purchase Agreement, dated May 10, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on May 11, 2023)
- Securities Purchase Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 14, 2023)
- Option and Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and RadioMedix, Inc., dated November 14, 2022 (Filed With SEC on February 14, 2023)
- Securities Purchase Agreement, dated February 13, 2023, by and among Fusion Pharmaceuticals Inc. and the Investors named therein (Filed With SEC on February 13, 2023)
- Option and Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and RadioMedix, Inc., dated November 14, 2022 (Filed With SEC on February 13, 2023)
- Amendment No. 2 to Asset Purchase Agreement, dated February 8, 2021, by and between Rainier Therapeutics, Inc. and the Company (Filed With SEC on March 25, 2021)
- Asset Purchase Agreement by and between Fusion Pharmaceuticals Inc. and Ipsen Pharma SAS, dated March 1, 2021 (Filed With SEC on March 2, 2021)
- Amendment No. 1 to Asset Purchase Agreement, dated October 8, 2020, by and between Fusion Pharmaceuticals Inc. and Rainier Therapeutics, Inc (Filed With SEC on November 10, 2020)
- Asset Purchase Agreement, dated as of March 10, 2020, by and between Rainier Therapeutics, Inc., Fortis Advisors LLC and the Registrant (Filed With SEC on June 5, 2020)
